Quebec – September 16, 2026 -- Devonian Health Group Inc. (TSXV: GSD) (OTCQB: DVHGF) expects its common shares and warrants to begin trading on NYSE American LLC as early as September 16, 2026, under the ticker symbols "DHGR" and "DHGR WS."
Devonian pursues dual listing tied to underwritten public offering
The proposed NYSE American listing is connected to an underwritten public offering of Devonian's common shares and warrants. The company will retain its existing listing on the TSX Venture Exchange and has reserved the symbol "DHGR" there, with plans to later change its TSXV ticker from "GSD" to "DHGR."
Listing remains contingent on NYSE American's final authorization
Trading commencement on NYSE American depends on market conditions and final approval of Devonian's listing application, as well as the company's continued compliance with exchange rules.
Devonian develops drugs for autoimmune fibroinflammatory diseases
Incorporated in 2015 and headquartered in Quebec, Canada, Devonian is a clinical-stage pharmaceutical company developing prescription drugs for fibroinflammatory autoimmune diseases, including atopic dermatitis, radiodermatitis and ulcerative colitis. The company operates a proprietary extraction facility at its Quebec headquarters.